文献速递心脑血管急症重症综合管理与镇静镇痛

机械取栓联合或不联合静脉溶栓对急性缺血性卒中功能结局的影响:SKIP随机临床试验

Effect of Mechanical Thrombectomy Without vs With Intravenous Thrombolysis on Functional Outcome Among Patients With Acute Ischemic Stroke: The SKIP Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01
一句话结论在急性大血管闭塞卒中患者中,单独机械取栓相比联合静脉溶栓未能证明功能结局的非劣效性,但置信区间宽也不能得出劣效结论。

SKIP试验为研究者发起的多中心、随机、开放标签、非劣效性临床试验,纳入204例急性大血管闭塞卒中患者,随机分为单独机械取栓组(n=101)与静脉溶栓(阿替普酶0.6 mg/kg)联合机械取栓组(n=103)。结论认为单独取栓未证明非劣效,但宽置信区间也不允许得出劣效结论。

要点

  • 在急性大血管闭塞卒中患者中,单独机械取栓90天良好功能结局(mRS 0-2)为59.4%,联合静脉溶栓为57.3%,差异2.1%(单侧97.5%CI -11.4%至∞),未达非劣效性。
  • 该试验中静脉溶栓使用阿替普酶0.6 mg/kg,并非通用推荐剂量,原文未提及其给药途径、频次或疗程。
  • 主要终点非劣效性未成立,但宽置信区间也不能得出单独取栓劣效的结论,临床决策需结合患者个体情况。

适用人群与场景

  • 纳入急性缺血性卒中 due to 大血管闭塞患者,年龄中位数74岁,男性62.7%,NIHSS评分中位数18,来自日本23家医院网络,2017年1月1日至2019年7月31日入组。
  • 原文未提及排除人群、急诊/ICU/院前具体场景或病情阶段。

诊断标准与关键阈值

  • 主要疗效终点为90天良好功能结局,定义为改良Rankin量表评分0-2(范围0无症症状至6死亡)。

处置流程与药物剂量

  • 干预组:机械取栓联合静脉溶栓,阿替普酶剂量0.6 mg/kg;原文未提及给药途径、频次、疗程或目标值。
  • 对照组:单独机械取栓;原文未提及具体取栓操作细节或围术期管理。

红旗征与不能漏的情况

  • 任何颅内出血在联合组更常见(50.5% vs 33.7%),需警惕出血风险,但原文未给出具体处理措施。
  • 症状性颅内出血发生率两组分别为5.9%和7.7%,原文未提及预防或处理方案。

研究设计与关键结果

  • 研究类型:研究者发起的多中心、随机、开放标签、非劣效性临床试验;样本量204例,23家医院网络,全部完成试验。
  • 干预与对照:单独机械取栓(n=101) vs 静脉溶栓(阿替普酶0.6 mg/kg)联合机械取栓(n=103)。

证据类型、等级与局限

  • 证据类型:随机对照试验(RCT),非劣效性设计,开放标签,多中心(23家医院网络),样本量204例。
  • 局限:原文未明确列出局限;设计上为开放标签、样本量较小、非劣效性未达到且置信区间宽。

对床旁实践的改变

  • 对于急性大血管闭塞卒中患者,单独机械取栓不能证明在90天良好功能结局上非劣于联合静脉溶栓,但也不能证明劣效,因此不能据此常规推荐省略静脉溶栓。
  • 单独机械取栓可能降低任何颅内出血风险(33.7% vs 50.5%),但症状性颅内出血无显著差异,需个体化权衡。
  • 试验中阿替普酶剂量为0.6 mg/kg,原文未提及其他剂量或给药方案,不能外推为通用推荐。
  • 适用与不适用人群:原文仅描述纳入急性大血管闭塞卒中患者,未明确排除标准,临床决策需结合患者具体情况。

指南或共识出处

  • SKIP随机临床试验,发表来源PubMed(JAMA),试验注册号UMIN000021488,原文未提及指南或共识名称。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Whether intravenous thrombolysis is needed in combination with mechanical thrombectomy in patients with acute large vessel occlusion stroke is unclear.

OBJECTIVE: To examine whether mechanical thrombectomy alone is noninferior to combined intravenous thrombolysis plus mechanical thrombectomy for favorable poststroke outcome.

DESIGN, SETTING, AND PARTICIPANTS: Investigator-initiated, multicenter, randomized, open-label, noninferiority clinical trial in 204 patients with acute ischemic stroke due to large vessel occlusion enrolled at 23 hospital networks in Japan from January 1, 2017, to July 31, 2019, with final follow-up on October 31, 2019.

INTERVENTIONS: Patients were randomly assigned to mechanical thrombectomy alone (n = 101) or combined intravenous thrombolysis (alteplase at a 0.6-mg/kg dose) plus mechanical thrombectomy (n = 103).

MAIN OUTCOMES AND MEASURES: The primary efficacy end point was a favorable outcome defined as a modified Rankin Scale score (range, 0 [no symptoms] to 6 [death]) of 0 to 2 at 90 days, with a noninferiority margin odds ratio of 0.74, assessed using a 1-sided significance threshold of .025 (97.5% CI). There were 7 prespecified secondary efficacy end points, including mortality by day 90. There were 4 prespecified safety end points, including any intracerebral hemorrhage and symptomatic intracerebral hemorrhage within 36 hours.

RESULTS: Among 204 patients (median age, 74 years; 62.7% men; median National Institutes of Health Stroke Scale score, 18), all patients completed the trial. Favorable outcome occurred in 60 patients (59.4%) in the mechanical thrombectomy alone group and 59 patients (57.3%) in the combined intravenous thrombolysis plus mechanical thrombectomy group, with no significant between-group difference (difference, 2.1% [1-sided 97.5% CI, -11.4% to ∞]; odds ratio, 1.09 [1-sided 97.5% CI, 0.63 to ∞]; P = .18 for noninferiority). Among the 7 secondary efficacy end points and 4 safety end points, 10 were not significantly different, including mortality at 90 days (8 [7.9%] vs 9 [8.7%]; difference, -0.8% [95% CI, -9.5% to 7.8%]; odds ratio, 0.90 [95% CI, 0.33 to 2.43]; P > .99). Any intracerebral hemorrhage was observed less frequently in the mechanical thrombectomy alone group than in the combined group (34 [33.7%] vs 52 [50.5%]; difference, -16.8% [95% CI, -32.1% to -1.6%]; odds ratio, 0.50 [95% CI, 0.28 to 0.88]; P = .02). Symptomatic intracerebral hemorrhage was not significantly different between groups (6 [5.9%] vs 8 [7.7%]; difference, -1.8% [95% CI, -9.7% to 6.1%]; odds ratio, 0.75 [95% CI, 0.25 to 2.24]; P = .78).

CONCLUSIONS AND RELEVANCE: Among patients with acute large vessel occlusion stroke, mechanical thrombectomy alone, compared with combined intravenous thrombolysis plus mechanical thrombectomy, failed to demonstrate noninferiority regarding favorable functional outcome. However, the wide confidence intervals around the effect estimate also did not allow a conclusion of inferiority.

TRIAL REGISTRATION: umin.ac.jp/ctr Identifier: UMIN000021488.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Suzuki K, Matsumaru Y, Takeuchi M, et al. Effect of Mechanical Thrombectomy Without vs With Intravenous Thrombolysis on Functional Outcome Among Patients With Acute Ischemic Stroke: The SKIP Randomized Clinical Trial. JAMA. 2021. PMID: 33464334. doi:10.1001/jama.2020.23522

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。